相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H. A. Muskiet et al.
NATURE REVIEWS NEPHROLOGY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
Srikanth Yandrapalli et al.
POSTGRADUATE MEDICINE (2017)
SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Mirko V. Sikirica et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita et al.
SCIENTIFIC REPORTS (2017)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
Ralph A. DeFronzo
DIABETES OBESITY & METABOLISM (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Honghong Zou et al.
CARDIOVASCULAR DIABETOLOGY (2017)
GLP-1 receptor agonists and heart failure in diabetes
Andre J. Scheen
DIABETES & METABOLISM (2017)
Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Guojing Luo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
Wataru Ogawa et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis
Patricia M. Howse et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
Ling Li et al.
BMC CARDIOVASCULAR DISORDERS (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Ronald M. Goldenberg et al.
CLINICAL THERAPEUTICS (2016)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
Sven Kohler et al.
CLINICAL THERAPEUTICS (2016)
GLP-1 Agonists and Blood Pressure: A Review of the Evidence
Aditya Goud et al.
CURRENT HYPERTENSION REPORTS (2016)
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
John P. H. Wilding et al.
DIABETES CARE (2016)
Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371-1377 RESPONSE
Ryan T. Crews et al.
DIABETES CARE (2016)
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
Lennart Tonneijck et al.
DIABETOLOGIA (2016)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
Kenneth B. Margulies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Chris E. Forsmark
PANCREATOLOGY (2016)
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Laurent Azoulay et al.
JAMA INTERNAL MEDICINE (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Jason H. Y. Wu et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Practical combination therapy based on pathophysiology of type 2 diabetes
Philip A. Levin
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
William T. Cefalu et al.
DIABETES CARE (2015)
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Francesco Giorgino et al.
DIABETES CARE (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Determinants of adherence to diabetes treatment
Amy T. Larkin et al.
JOURNAL OF DIABETES (2015)
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
Carlo B. Giorda et al.
ENDOCRINE (2015)
Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
Mohammad Katout et al.
AMERICAN JOURNAL OF HYPERTENSION (2014)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
S. Bonner-Weir et al.
DIABETES OBESITY & METABOLISM (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
Raymond V. Oliva et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
The perils of clinical trials
Richard E. Gilbert
KIDNEY INTERNATIONAL (2014)
Effects of GLP-1 in the Kidney
Jeppe Skov
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2014)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium-Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Timothy P. Reilly et al.
DIABETES THERAPY (2014)
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
E. Raschi et al.
ACTA DIABETOLOGICA (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Ele Ferrannini et al.
DIABETES CARE (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis
Lin Yang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pancreatitis-Diabetes-Pancreatic Cancer
Dana K. Andersen et al.
PANCREAS (2013)
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
Louise E. Robinson et al.
BMJ OPEN (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus
G. S. Hillis et al.
DIABETOLOGIA (2012)
The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
Scott E. Kanoski et al.
NEUROPHARMACOLOGY (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women
Marie Therese Cooney et al.
AMERICAN HEART JOURNAL (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis
P. Vestergaard
OSTEOPOROSIS INTERNATIONAL (2007)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
MS Fineman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Diabetes and risk of fracture - The Blue Mountains Eye Study
RQ Ivers et al.
DIABETES CARE (2001)
分享论文
